Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
NCT ID: NCT00669903
Last Updated: 2010-08-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
100 participants
INTERVENTIONAL
2008-04-30
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
NCT00528905
A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia
NCT03356639
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
NCT00986531
In-Patient Study In Schizophrenic Patients
NCT00197093
Clinical Trial of AVL-3288 in Schizophrenia Patients
NCT02978599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AZD0328 low dose
AZD0328
2
AZD0328 Optimal dose
AZD0328
3
AZD0328 High dose
AZD0328
4
Placebo Comparator
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD0328
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Low level of Extra-pyramidal symptoms
* No clinically significant findings on physical examination
Exclusion Criteria
* Any significant psychiatric or neurological disease other than schizophrenia
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Center
Garden Grove, California, United States
Research Center
Glendale, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D0190C00007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.